about
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy[Bernard-Soulier syndrome during pregnancy: a case report].Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).[Thrombocytopenia during pregnancy]Antisense strategy in hematological malignancies.Isolated extramedullary breast relapses in inv(16) positive and c-KIT negative acute myeloid leukemia after allogenic hematopoietic stem cell transplantation - description of two casesCladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor-alpha and its Muteins on Leukaemia L1210 and Leukaemia P388 in MiceThe influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor-alpha or its mutein on murine leukaemias L1210 and P388.Potential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria.Host immune response in B-cell lymphomas: friend or foe?Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.Haematological parameters in postpartum women and their babies in Poland - comparison of urban and rural areas.Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes.Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.[Necrotizing gastritis in a patient in severe neutropenia].Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.Beneficial effect of the CXCL12-3'A variant for patients undergoing hematopoietic stem cell transplantation from unrelated donors.Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland.NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.Diagnostic and therapeutic quandaries in primary manifestation of Hodgkin's disease in the central nervous system.
P50
Q28472420-2C6EFAD4-3CC9-47E3-B03F-1E02C02300BAQ28552218-9363BA25-A21B-4CD1-AFFF-344CDABCB1BCQ33369952-004DE6F6-A64B-4D65-9DBA-58BF2E8368E3Q33391987-2525EE2D-D540-450A-B192-7D3F2CA4CB00Q33406598-76B7CCF6-FC19-4891-9955-0F319E0B0041Q33412849-78FF44E3-ABD7-419D-9412-C4F73CF0B040Q33417762-34E3ED5C-46B2-4F60-AB23-F252610ECCB5Q33424228-7FBF5FCD-D468-406C-9F81-A6079EEB1849Q33491874-7AC71257-DFB3-4F67-9285-E6033C66B83AQ33676682-CBAB76A9-2F7A-4AF9-8D5F-FA771ED6A710Q33935391-D384AD4F-F702-4936-9B76-CB2ABB95679CQ34599136-F60FCFD1-6D35-4CD1-822D-7C67589FF302Q34637551-482989BD-07AE-4182-BE2F-07E1D9B60BC3Q36292902-D171A921-99E3-442C-8850-6277BCA9D058Q36627658-C92B13C8-E17A-4D97-921D-5E3ED2102D8DQ36627726-9B8AEF39-2915-47F2-A13E-D6C89177F1FEQ36695249-F7250B1F-6B0D-4FCD-B521-4772600F84A4Q37251809-BAD4D58E-1BC6-4D53-817C-C0345585B1BFQ38376612-A0A1FA29-56D1-49A4-BF76-288DC5F19816Q38683489-CCC336CB-C266-4571-B071-982F952ED544Q38741906-874856E7-79D3-4B98-A1DB-04CFF90012CAQ38978727-9633E914-094D-4ADF-8088-73236EE10A2AQ39806627-195E7B20-8B00-4889-832E-4822499045CFQ40014628-29C1E9AE-3566-4C07-86D7-43DF31BABA74Q40373192-F518BE81-B269-4101-BCD9-C312050B8125Q40424735-2CB1ED38-297C-4A8B-B541-3A1CF879FB18Q40439390-F7A39C13-F275-4034-802C-AB6281E7964DQ40518271-DE838DA0-8F62-443A-B9C7-63D15D65FBC1Q40590761-1E5C5346-4055-4951-86A5-9D066116B168Q41050317-CEFF3AAA-3C59-4D4A-9ED5-C3B83B7DEAE3Q41111760-C089FD7D-92F9-4D7A-9EB7-E219C5A495EBQ41240646-1E35F863-2387-4E11-B4C0-4C8567D5DFE8Q41464069-F1A9094A-12C9-4FF8-B114-9B4A5ECD236FQ41532474-B6E5CD88-B5D7-4208-B880-2905BC9C1EA2Q41607636-054AE103-C1AE-403D-B3CC-B867E4E6E9C9Q41732815-D71874FF-53DC-4FF2-8900-96C6B2971343Q41810975-ED65254A-27F7-41E3-9393-889C94FE646FQ42248606-A47B4E16-020B-46E8-A469-DE4E9AD42668Q42380779-9C37900B-B6AF-4700-A769-E02262900B2BQ42521703-4C3D678C-E1E7-4C44-93FB-90E068EE81AD
P50
description
researcher ORCID ID = 0000-0002-2396-3905
@en
wetenschapper
@nl
name
Krzysztof Warzocha
@ast
Krzysztof Warzocha
@en
Krzysztof Warzocha
@es
Krzysztof Warzocha
@nl
type
label
Krzysztof Warzocha
@ast
Krzysztof Warzocha
@en
Krzysztof Warzocha
@es
Krzysztof Warzocha
@nl
prefLabel
Krzysztof Warzocha
@ast
Krzysztof Warzocha
@en
Krzysztof Warzocha
@es
Krzysztof Warzocha
@nl
P1153
35480413700
P31
P496
0000-0002-2396-3905